AFLAC Incorporated (AFL) Stock Price Today
Aura AI Summary
Key Stats
- $61.32BMARKET_CAP
- -VOLUME
- FinancialsSECTOR
- $120.88FIFTY_TWO_WEEK_HIGH
- $98.09FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $69.99BENTERPRISE_VALUE
- 2.03%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track AFLAC Incorporated (AFL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, AFLAC Incorporated has traded between a low of $98.09 and a high of $120.88, highlighting its annual price range. Buy and sell AFLAC Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Most Recent News
GrowGeneration joins U.S. Cannabis Roundtable to influence federal cannabis policy and support industry growth.
GrowGeneration Corp., a leading supplier for controlled environment agriculture, has joined the U.S. Cannabis Roundtable (USCR) to help shape federal cannabis regulations. Represented by CEO Darren Lampert, GrowGeneration aims to leverage its agricul...

Zapata Quantum CEO to present on NVIDIA collaboration and quantum cancer research at July 9 investor conference
Zapata Quantum announced that CEO Sumit Kapur will present live at the Global Technology Virtual Investor Conference on July 9, highlighting the company's collaboration with NVIDIA to accelerate quantum algorithm development and its quantum-enabled c...

Transthyretin Amyloidosis Treatment Market to hit $35.1B by 2035, growing at 14.64% CAGR driven by new RNAi therapies and diagnostics.
The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to reach $35.10 billion by 2035 with a CAGR of 14.64%. Growth is fueled by advances in gene-silencing RNAi therapies like patisiran and vutrisiran, i...
